FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224224975> ?p ?o ?g. }

• W4224224975 endingPage "551" @default.
• W4224224975 startingPage "541" @default.
• W4224224975 abstract "This study evaluated from a US payer perspective the cost-effectiveness of two chimeric antigen receptor T (CAR T) cell therapies, axicabtagene ciloleucel (axi-cel) versus lisocabtagene maraleucel (liso-cel), for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) following two or more systemic therapy lines.We developed a 3-state (i.e., pre-progression, post-progression, death) partitioned survival model to estimate patients' lifetime outcomes. Mixture cure models were used for survival extrapolation to account for long-term remission. Survival inputs were based on a matching-adjusted indirect comparison (MAIC) that reweighted the ZUMA-1 population (receiving axi-cel) to match patient characteristics in TRANSCEND-NHL-001 (assessing liso-cel). Costs included apheresis, drug acquisition, and administration for conditioning chemotherapy and CAR T therapies, monitoring, transplant, hospitalization, adverse events, routine care, and terminal care, per published literature and databases. Utilities were derived from ZUMA-1 and literature. Deterministic and probabilistic sensitivity analyses were conducted.In the base case, axi-cel was associated with more QALYs (7.76 vs. 5.94) and greater costs overall ($611,440 vs. $597,174) than liso-cel, at $7,843/QALY gained. The incremental costs (+$14,266) were largely driven by higher routine care costs (+$18,596) due to longer survival and hospitalization (+$10,993) but partially offset by reduced costs of CAR T acquisition (‒$11,300) and terminal care (‒$4,025). Sensitivity analyses consistently suggested robustness of base-case results.This study relied on an MAIC in which trial design differences and unobserved confounders could not be accounted for. Future real-world studies for recently approved CAR T are warranted to validate our results. Due to a lack of data, we assumed equivalent use of transplants and treatment for B-cell aplasia between the two therapies based on clinicians' opinions.In the US, axi-cel is a potentially cost-effective treatment option compared with liso-cel for adult patients with r/r LBCL after two or more systemic therapy lines." @default.
• W4224224975 created "2022-04-26" @default.
• W4224224975 creator A5010239411 @default.
• W4224224975 creator A5021394406 @default.
• W4224224975 creator A5027316831 @default.
• W4224224975 creator A5030572351 @default.
• W4224224975 creator A5031229041 @default.
• W4224224975 creator A5035175326 @default.
• W4224224975 creator A5050095307 @default.
• W4224224975 creator A5084342658 @default.
• W4224224975 date "2022-05-02" @default.
• W4224224975 modified "2023-10-16" @default.
• W4224224975 title "Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US" @default.
• W4224224975 cites W1972744813 @default.
• W4224224975 cites W1982967337 @default.
• W4224224975 cites W2098914901 @default.
• W4224224975 cites W2133345449 @default.
• W4224224975 cites W2134365788 @default.
• W4224224975 cites W2150587745 @default.
• W4224224975 cites W2174429140 @default.
• W4224224975 cites W2382078359 @default.
• W4224224975 cites W2470555690 @default.
• W4224224975 cites W2567289819 @default.
• W4224224975 cites W2729210473 @default.
• W4224224975 cites W2744261860 @default.
• W4224224975 cites W2765198305 @default.
• W4224224975 cites W2773804840 @default.
• W4224224975 cites W2810179171 @default.
• W4224224975 cites W2893050608 @default.
• W4224224975 cites W2917035693 @default.
• W4224224975 cites W2920602503 @default.
• W4224224975 cites W2948047060 @default.
• W4224224975 cites W2984402712 @default.
• W4224224975 cites W2985291210 @default.
• W4224224975 cites W2990867581 @default.
• W4224224975 cites W3035443948 @default.
• W4224224975 cites W3082855561 @default.
• W4224224975 cites W3095453737 @default.
• W4224224975 cites W3134462904 @default.
• W4224224975 cites W3139382474 @default.
• W4224224975 cites W3142450396 @default.
• W4224224975 cites W3157319952 @default.
• W4224224975 cites W3185183014 @default.
• W4224224975 cites W3197223132 @default.
• W4224224975 cites W3197318668 @default.
• W4224224975 cites W3212944538 @default.
• W4224224975 cites W3213274776 @default.
• W4224224975 cites W4205907103 @default.
• W4224224975 cites W4249178543 @default.
• W4224224975 doi "https://doi.org/10.1080/13696998.2022.2065787" @default.
• W4224224975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35443867" @default.
• W4224224975 hasPublicationYear "2022" @default.
• W4224224975 type Work @default.
• W4224224975 citedByCount "4" @default.
• W4224224975 countsByYear W42242249752022 @default.
• W4224224975 countsByYear W42242249752023 @default.
• W4224224975 crossrefType "journal-article" @default.
• W4224224975 hasAuthorship W4224224975A5010239411 @default.
• W4224224975 hasAuthorship W4224224975A5021394406 @default.
• W4224224975 hasAuthorship W4224224975A5027316831 @default.
• W4224224975 hasAuthorship W4224224975A5030572351 @default.
• W4224224975 hasAuthorship W4224224975A5031229041 @default.
• W4224224975 hasAuthorship W4224224975A5035175326 @default.
• W4224224975 hasAuthorship W4224224975A5050095307 @default.
• W4224224975 hasAuthorship W4224224975A5084342658 @default.
• W4224224975 hasBestOaLocation W42242249751 @default.
• W4224224975 hasConcept C112930515 @default.
• W4224224975 hasConcept C126322002 @default.
• W4224224975 hasConcept C143998085 @default.
• W4224224975 hasConcept C2779338263 @default.
• W4224224975 hasConcept C2908647359 @default.
• W4224224975 hasConcept C3019080777 @default.
• W4224224975 hasConcept C71924100 @default.
• W4224224975 hasConcept C99454951 @default.
• W4224224975 hasConceptScore W4224224975C112930515 @default.
• W4224224975 hasConceptScore W4224224975C126322002 @default.
• W4224224975 hasConceptScore W4224224975C143998085 @default.
• W4224224975 hasConceptScore W4224224975C2779338263 @default.
• W4224224975 hasConceptScore W4224224975C2908647359 @default.
• W4224224975 hasConceptScore W4224224975C3019080777 @default.
• W4224224975 hasConceptScore W4224224975C71924100 @default.
• W4224224975 hasConceptScore W4224224975C99454951 @default.
• W4224224975 hasIssue "1" @default.
• W4224224975 hasLocation W42242249751 @default.
• W4224224975 hasLocation W42242249752 @default.
• W4224224975 hasOpenAccess W4224224975 @default.
• W4224224975 hasPrimaryLocation W42242249751 @default.
• W4224224975 hasRelatedWork W1994029314 @default.
• W4224224975 hasRelatedWork W2042069958 @default.
• W4224224975 hasRelatedWork W2092885581 @default.
• W4224224975 hasRelatedWork W2095950656 @default.
• W4224224975 hasRelatedWork W2189819889 @default.
• W4224224975 hasRelatedWork W2340462751 @default.
• W4224224975 hasRelatedWork W2899615166 @default.
• W4224224975 hasRelatedWork W2912565296 @default.
• W4224224975 hasRelatedWork W3134070153 @default.
• W4224224975 hasRelatedWork W4284700853 @default.
• W4224224975 hasVolume "25" @default.

• next